Intercept Pharma (ICPT) Tops Q3 EPS by 98c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
November 3, 2021 7:00 AM EDTWorldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter
Company increases 2021 guidance of Ocaliva net sales to $355 million to $370 million and narrows Non-GAAP adjusted operating expense guidance to $380 to $395 million
NASH data generation remains on track
New PBC POISE long-term data accepted in a late-breaking presentation at The Liver Meeting® next month
Completed successful debt exchange and share buy back
Company to host conference call today at 8:30 a.m.... More
